W Fischbach

Summary

Affiliation: Medizinische Klinik II
Country: Germany

Publications

  1. ncbi Comparative analysis of the Helicobacter pylori status in patients with gastric MALT-type lymphoma and their respective spouses
    W Fischbach
    Medizinische Klinik II, Klinikum Aschaffenburg, Akademisches Lehrkrankenhaus, Universitat Wurzburg
    Z Gastroenterol 38:627-30. 2000
  2. ncbi Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of Helicobacter pylori can be managed safely by a watch and wait strategy: experience from a large international series
    W Fischbach
    Department of Internal Medicine II, Klinikum Aschaffenburg, Aschaffenburg, Germany
    Gut 56:1685-7. 2007
  3. ncbi [Gastrointestinal lymphomas]
    W Fischbach
    Medizinische Klinik II, Klinikum Aschaffenburg, Akademisches Lehrkrankenhaus der Julius Maximilians Universität Würzburg
    Z Gastroenterol 42:1067-72. 2004
  4. ncbi [58th General Meeting of the DGVS in Nuremberg]
    W Fischbach
    Medizinische Klinik II, Klinikum Aschaffenburg
    Z Gastroenterol 42:187-92. 2004
  5. ncbi Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series
    W Fischbach
    Department of Internal Medicine, Klinikum Aschaffenburg, Aschaffenburg, Germany
    Gut 53:34-7. 2004
  6. ncbi [Gastrointestinal lymphoma]
    W Fischbach
    Medizinische Klinik II, Klinikum Aschaffenburg
    Dtsch Med Wochenschr 128:1899-901. 2003
  7. ncbi Primary gastric lymphoma of MALT: considerations of pathogenesis, diagnosis and therapy
    W Fischbach
    Medizinische Klinik II, Klinikum Aschaffenburg, Aschaffenburg, Germany
    Can J Gastroenterol 14:44D-50D. 2000
  8. ncbi [Intestinal lymphomas]
    W Fischbach
    Medizinische Klinik II, Klinikum Aschaffenburg
    Dtsch Med Wochenschr 128:S72-4. 2003
  9. ncbi S3-guideline "helicobacter pylori and gastroduodenal ulcer disease" of the German society for digestive and metabolic diseases (DGVS) in cooperation with the German society for hygiene and microbiology, society for pediatric gastroenterology and
    W Fischbach
    Medizinische Klinik II, Klinikum Aschaffenburg
    Z Gastroenterol 47:1230-63. 2009
  10. ncbi [Gastric lyphoma - still a result of surgery?]
    W Fischbach
    Medizinische Klinik II, Klinikum Aschaffenburg, Lehrkrankenhaus der Universität Würzburg, Am Hasenkopf, 63739 Aschaffenburg
    Chirurg 77:512, 514-7. 2006

Detail Information

Publications33

  1. ncbi Comparative analysis of the Helicobacter pylori status in patients with gastric MALT-type lymphoma and their respective spouses
    W Fischbach
    Medizinische Klinik II, Klinikum Aschaffenburg, Akademisches Lehrkrankenhaus, Universitat Wurzburg
    Z Gastroenterol 38:627-30. 2000
    ..In case of localized low grade lymphoma successfully treated by Helicobacter pylori eradication reinfection by the bacterium may involve the risk of lymphoma reoccurrence...
  2. ncbi Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of Helicobacter pylori can be managed safely by a watch and wait strategy: experience from a large international series
    W Fischbach
    Department of Internal Medicine II, Klinikum Aschaffenburg, Aschaffenburg, Germany
    Gut 56:1685-7. 2007
    ..Patients with minimal persisting lymphoma infiltrates after successful eradication of H pylori are considered treatment failures and referred for radiation, chemotherapy, immunotherapy, or surgery...
  3. ncbi [Gastrointestinal lymphomas]
    W Fischbach
    Medizinische Klinik II, Klinikum Aschaffenburg, Akademisches Lehrkrankenhaus der Julius Maximilians Universität Würzburg
    Z Gastroenterol 42:1067-72. 2004
    ..However, also a watch-and-wait strategy may be a good choice in the individual case (minimal residual disease after successful Helicobacter pylori eradication or disseminated stages of indolent lymphomas not offering a curative option)...
  4. ncbi [58th General Meeting of the DGVS in Nuremberg]
    W Fischbach
    Medizinische Klinik II, Klinikum Aschaffenburg
    Z Gastroenterol 42:187-92. 2004
  5. ncbi Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series
    W Fischbach
    Department of Internal Medicine, Klinikum Aschaffenburg, Aschaffenburg, Germany
    Gut 53:34-7. 2004
    ..Helicobacter pylori plays a decisive role in the pathogenesis of gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT), and eradication therapy has become a widely accepted initial treatment of stage I disease...
  6. ncbi [Gastrointestinal lymphoma]
    W Fischbach
    Medizinische Klinik II, Klinikum Aschaffenburg
    Dtsch Med Wochenschr 128:1899-901. 2003
  7. ncbi Primary gastric lymphoma of MALT: considerations of pathogenesis, diagnosis and therapy
    W Fischbach
    Medizinische Klinik II, Klinikum Aschaffenburg, Aschaffenburg, Germany
    Can J Gastroenterol 14:44D-50D. 2000
    ..There is a need to clarify whether operative or conservative therapeutic strategies should be favoured in the future...
  8. ncbi [Intestinal lymphomas]
    W Fischbach
    Medizinische Klinik II, Klinikum Aschaffenburg
    Dtsch Med Wochenschr 128:S72-4. 2003
  9. ncbi S3-guideline "helicobacter pylori and gastroduodenal ulcer disease" of the German society for digestive and metabolic diseases (DGVS) in cooperation with the German society for hygiene and microbiology, society for pediatric gastroenterology and
    W Fischbach
    Medizinische Klinik II, Klinikum Aschaffenburg
    Z Gastroenterol 47:1230-63. 2009
    ..Clinical applicability of study results as well as specifics for Germany in terms of epidemiology, antibiotic resistance status, diagnostics, and therapy were taken into account...
  10. ncbi [Gastric lyphoma - still a result of surgery?]
    W Fischbach
    Medizinische Klinik II, Klinikum Aschaffenburg, Lehrkrankenhaus der Universität Würzburg, Am Hasenkopf, 63739 Aschaffenburg
    Chirurg 77:512, 514-7. 2006
    ..This review examines current views on pathogenesis, diagnosis, and therapy of this disorder...
  11. ncbi [S3-guideline "Helicobacter pylori and gastroduodenal ulcer disease"]
    W Fischbach
    Medizinische Klinik II, Klinikum Aschaffenburg, Akad Lehrkrankenhaus der Universität Würzburg, Aschaffenburg
    Z Gastroenterol 47:68-102. 2009
    ..Clinical applicability of study results as well as specifics for Germany in terms of epidemiology, antibiotic resistance status, diagnostics and therapy were taken into account...
  12. ncbi [Palliative treatment for colorectal cancer]
    D Flieger
    Medizinische Klinik II, Klinikum Aschaffenburg
    Internist (Berl) 45:786-94. 2004
    ..Considering the variety of therapeutic options, it is prudent to discuss individual treatment plans in an interdisciplinary "tumor board" and involve the practitioners in the decision making...
  13. ncbi [Gastric MALT-type lymphoma. Pathology, pathogenesis, diagnostics and therapy]
    M Eck
    Institut fur Pathologie, Klinikum Aschaffenburg, Am Hasenkopf 63704, Aschaffenburg
    Pathologe 31:188-94. 2010
    ..Therapy modalities are H. pylori eradication, radiochemotherapy, surgery or a combination of these. Aim of the therapy is the complete lymphoma regression and cure of the disease...
  14. ncbi Long-term follow-up of gastric lymphoma after stomach conserving treatment
    W Fischbach
    Medizinische Klinik II und Klinik für Palliativmedizin, Klinikum Aschaffenburg, Akademisches Lehrkrankenhaus der Universität Würzburg, Germany
    Best Pract Res Clin Gastroenterol 24:71-7. 2010
    ..pylori status as the determinants of the choice of treatment. Efficacy and quality of life are strong arguments for a definite conservative approach encompassing H. pylori eradication, radiation and chemotherapy...
  15. ncbi [Therapeutic strategies in colorectal cancer]
    D Flieger
    Medizinische Klinik II, Aschaffenburg
    Dtsch Med Wochenschr 128:1902-7. 2003
  16. ncbi [Role of endoscopic ultrasound in gastrointestinal lymphomas]
    O H Al-Taie
    Medizinische Klinik II, Klinikum Aschaffenburg
    Z Gastroenterol 46:618-24. 2008
    ..There is no clear correlation between histologically proven residual disease and endosonographic results. Thus, so far, endoscopic ultrasound will not replace bioptic surveillance after MALT lymphoma treatment...
  17. ncbi Capsule endoscopy in gastrointestinal lymphomas
    D Flieger
    Dept of Internal Medicine II, Aschaffenburg Hospital, Aschaffenburg, Germany
    Endoscopy 37:1174-80. 2005
    ..The aim of this prospective study was to assess the frequency and morphology of different forms of intestinal pathology in patients with gastrointestinal lymphomas...
  18. ncbi Staging role of EUS
    W Fischbach
    Medizinische Klinik II und Klinik für Palliativmedizin, Klinikum Aschaffenburg, Akademisches Lehrkrankenhaus der Universität Würzburg, Germany
    Best Pract Res Clin Gastroenterol 24:13-7. 2010
    ..On the contrary, EUS cannot be recommended as a regular part of follow-up investigations considering its limited value in predicting the response of the lymphoma to radiation or chemotherapy...
  19. ncbi Outcome and quality of life favour a conservative treatment of patients with primary gastric lymphoma
    W Fischbach
    Medizinische Klinik II, Klinikum Aschaffenburg
    Z Gastroenterol 49:430-5. 2011
    ..No comparison of surgical resection with primary radiation or chemotherapy on a prospective randomised basis was available up to now...
  20. ncbi [Helicobacter pylori infection in children and juveniles: an epidemiological study on prevalence, socio-economic factors and symptoms]
    W Grimm
    Medizinische Klinik II, Klinikum Aschaffenburg,
    Dtsch Med Wochenschr 128:1878-83. 2003
    ..p. infection. CONCLUSION: This study highlights the importance of socio-economic factors and the possible association of upper abdominal pain with H.p infection...
  21. ncbi [Endoscopic-bioptic diagnostics, surveillance of and therapy for gastrointestinal diseases according to guidelines]
    S Warich-Eitel
    Institut fur Pathologie, Klinikum Aschaffenburg, Aschaffenburg
    Z Gastroenterol 48:414-9. 2010
    ..To allow the gastroenterologist a time-sparing overview during practical work, most of the recommendations are presented in itemised form and summarised in tables and figures at the end of the discussion...
  22. ncbi Better acceptance of Fecal Occult Blood Test (FOBT) for colorectal cancer screening during hospitalization
    R Keller
    Medizinische Klinik II, Klinikum Aschaffenburg
    Z Gastroenterol 41:655-8. 2003
    ..However, motivation to regularly repeat screening does not last in all patients. Therefore, public campaigns as well as medical counseling need to continuously stress the necessity of CRC screening procedures...
  23. ncbi Unusual treatment of a gastric marginal zone B-cell lymphoma of MALT type
    W Fischbach
    Medizinische Klinik II, Klinikum Aschaffenburg, Akademisches Lehrkrankenhaus der Universität Würzburg, Aschaffenburg, Germany
    Z Gastroenterol 45:383-6. 2007
    ....
  24. ncbi [Helicobacter pylori]
    W Fischbach
    Medizinische Klinik II und Klinik für Palliativmedizin, Klinikum Aschaffenburg, Akad Lehrkrankenhaus der Universität Würzburg, Am Hasenkopf, Aschaffenburg, Germany
    Internist (Berl) 50:979-86; quiz 987. 2009
    ..First-line therapy is performed with a 7-days combination of proton pump inhibitor with clarithromycin and amoxicillin or metronidazole. In second-line therapy levofloxacin and rifabutin are good rescue antibiotics...
  25. ncbi [Interdisciplinary clinical pathway for colorectal cancer]
    W Fischbach
    Medizinische Klinik II, Klinikum Aschaffenburg, Akademisches Lehrkrankenhaus der Universität Würzburg
    Internist (Berl) 47:720-3, 725-8. 2006
    ..The potential of such pathways to save costs as well as their implications on treatment results and patients' satisfaction will have to be critically analyzed in the future before their value can be definitely estimated...
  26. ncbi Interrelation between ABH blood group 0, Lewis(B) blood group antigen, Helicobacter pylori infection, and occurrence of peptic ulcer
    R Keller
    Medizinische Klinik II, Klinikum Aschaffenburg, Aschaffenburg, Germany
    Z Gastroenterol 40:273-6. 2002
    ..Determination of ABH blood groups or secretor status is, therefore, not a useful tool to characterize the individual risk for gastroduodenal ulcer or to guide any diagnostic procedures...
  27. ncbi [MALT-lymphoma]
    D Flieger
    Medizinische Klinik, GP Klinikum Russelsheim
    Praxis (Bern 1994) 95:1163-8. 2006
    ..For both entities a further improvement may be achieved in ongoing prospective clinical trials by addition of the monoclonal antibody rituximab, which targets CD20 on lymphoma cells...
  28. ncbi Incidence of gastric B-cell lymphomas: a population-based study in Germany
    A Ullrich
    School of Public Health, Department of Epidemiology and Medical Statistics, University of Bielefeld, Bielefeld
    Ann Oncol 13:1120-7. 2002
    ..While the clinical and experimental knowledge concerning gastric lymphomas is increasing, there is a scarcity of epidemiological data...
  29. ncbi [Current therapy concepts of stomach lymphoma]
    W Fischbach
    Medizinische Klink Aschaffenburg
    Z Gastroenterol 40:24-6. 2002
  30. ncbi [Trends in gastroenterology]
    W Fischbach
    Dtsch Med Wochenschr 128:1877. 2003
  31. ncbi Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia
    P Malfertheiner
    Otto von Guericke Universitat, Zentrum fur Innere Medizin, Magdeburg, Germany
    Aliment Pharmacol Ther 18:615-25. 2003
    ..To assess whether the eradication of Helicobacter pylori leads to long-term relief of symptoms in functional dyspepsia...
  32. ncbi Autoantibodies in gastric MALT-type lymphoma
    M Eck
    Ann Oncol 14:1153-4. 2003
  33. ncbi [Topic complex VII: Surgical therapy]
    K H Fuchs
    Z Gastroenterol 43:191-4. 2005